Is it cheap or expensive right now?

Latest price vs our fair value. A comparison, not a recommendation.

In plain terms: the company has just finished a USD 100 million biologicals plant. From FY2026 its AED 4,901 million construction balance — larger than the entire depreciated property base before it — starts depreciating, and this study charges every pound of that while crediting the plant with NO revenue, because the company has published none. That is why the fundamental readings cluster at AED 58–73 against a price of AED 130.05. Read the other way: the market is paying AED 72.01 a share, 55% of the price, for that plant — roughly 2.1 times what it cost to build — which needs about USD 120 million a year of biosimilar revenue by FY2030 to justify. That is the bet, and it is a number the company will eventually disclose.

Key levels

The 5th–95th and 25th–75th percentile bands from the 50,000-path simulation. Static and pre-computed — independent of the fundamental value.

What drives the odds

One Monte Carlo model, 50,000 paths, driven by the outside forces relevant to a hard-currency industrial exporter listed in a soft-currency market: the LME copper price, the AED/USD path, the CBE policy corridor and the pace of easing, the United Arab Emiratesian inflation, Gulf and North African grid and infrastructure spending, the order book and its conversion rate, interconnector and data-centre demand for cable and transformers, energy and freight costs, convertibility and repatriation risk on the foreign earnings, and the free float — 11.6% of the shares, with 68% held by the family and 20% by Electra, which is what makes the tape thin. Full mechanics in the methodology.